We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
*Update 22 July 2020*
Please note that that Associate Professor Radford’s work has not yet progressed to human clinical trials. We need your help to make this happen.
Your donation will make a direct impact to the lives of people living with cancer today. Support clinical trials.
Mater Researchers have achieved publication in the highly-ranked journal, Clinical and Translational Immunology detailing their work on a new cancer vaccine, which has shown promising signs in preclinical laboratory studies.
The vaccine was developed with support from Worldwide Cancer Research in the United Kingdom, and Mater Foundation, and could potentially be used to treat a variety of blood cancers and malignancies.
Lead Researcher Associate Professor Kristen Radford said this was a major breakthrough when it came to cancer vaccinations.
“We are hoping this could be used to treat blood cancers (myeloid leukaemia, non-Hodgkin’s lymphoma, multiple myeloma, paediatric leukaemias) plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma,” she said.
“The team have developed a new vaccine, comprised of human antibodies fused with tumour-specific protein, and are investigating its capacity to target human cells while activating the memory of the tumour cells.”
Associate Professor Radford explains that the vaccine offers several key advantages over existing cancer vaccines that have already shown promise in early clinical trials.
“First, it can be produced as an ‘off the shelf’ clinical grade formulation, which circumvents the ﬁnancial and logistical issues associated with patient-speciﬁc vaccines,” she said.
“Second, this prototype vaccine precisely targets the key tumour cells required for the initiation of tumour speciﬁc immune responses, thereby maximising potential efﬁcacy while minimising potential side effects.
“We are very happy to see our research published in this prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future.”
You can read the full academic article here at, http://dx.doi.org/10.1002/cti2.1141
07 3163 1524
07 3163 6142
This week Shwe’s hopes of following in her parent’s footsteps of care and healing were formally realised, when she graduated with a Diploma of Nursing through Mater ...
On 28 July Mater Private Hospital Bundaberg celebrated 75 years of serving the community with a celebratory mass to mark the anniversary of hospital opening its doors ...
Did you know 1 in 12 children aged between 3-17 will experience a disorder related to voice, speech, language, communication or swallowing?* While these disorders are ...
On the 28 July each year, World Hepatitis Day is held to raise awareness of the global burden of viral hepatitis and to influence change in the community.